FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 329:1280-1281 October 21, 1993 Number 17 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

To the Editor: Filgrastim (recombinant human granulocyte colony-stimulating factor) is available for the treatment of chemotherapy-induced neutropenia. It is currently being investigated for use in bone marrow transplantation, aplastic anemia, myelodysplastic syndrome, and other chronic neutropenic states. The currently recommended doses of 120 to 350 µg per square meter of body-surface area are based on data on the treatment of chemotherapy-induced neutropenia, which is aimed at inducing proliferation of progenitor cells that have been depleted^1,2,3. Many chronic neutropenic states, however, are characterized by ineffective hematopoiesis. In this situation, there is peripheral-blood cytopenia although the bone marrow is normocellular or . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.